Access cutting-edge type1diabetes treatment through this clinical trial at a research site in Atlanta. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Atlanta location
Preparing your pre-screening questions…
Access type1diabetes specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related type1diabetes treatment provided free
Check if you qualify for this type1diabetes clinical trial in Atlanta, GA
No-Cost Study Care
Local to Atlanta
Convenient for GA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Type 1 diabetes (T1D) affects approximately 2 million Americans, and only 2 in 8 young adults ages 18-31 years achieve glycemic targets (glycated hemoglobin A1C \<7.0%). Achieving glycemic targets is associated with reduced risk of micro-and macrovascular complications. Sleep deprivation leads to impaired glucose tolerance and insulin sensitivity in adults without chronic conditions and with T1D. Promoting sleep in laboratory and natural environments contributes to improvements in insulin sensitivity, glucose levels, and distress symptoms in young adults without chronic conditions and more time in range in adolescents with T1D. Multiple dimensions of sleep health (alertness, timing, efficiency, and sleep duration) are associated with better achievement of glycemic targets in adults with T1D. Therefore, sleep health dimensions are appropriate therapeutic targets to improve glucoregulation and other diabetes self-management outcomes in this population. Our primary objective is to evaluate the immediate and short-term effects of a 12-week CB-sleep intervention compared to enhanced usual care (time balanced attention control) on actigraphy- and self-report derived sleep health dimensions and diabetes self-management outcomes (glycemia and distress symptoms) over 9-months (Stage II of the NIH Model for Behavior Change, ORBIT phase III). CB-sleep is guided by principles and practices from motivational interviewing and the Transtheoretical Model of Behavior Change with interactive stage-matched sessions.
Sponsor: Emory University
Yes, this clinical trial (NCT05823142) has an active research site in Atlanta, GA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for type1diabetes treatment options in Atlanta, GA, this clinical trial (NCT05823142) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Atlanta research site is actively enrolling participants for this clinical trial. You'll receive care from experienced type1diabetes specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all type1diabetes clinical trials near you to find additional studies recruiting in your area.
See all pulmonary embolism clinical trials recruiting in Atlanta — not just this study.
Browse Pulmonary Embolism Trials in Atlanta →